T VOBIT 2 10'S

About

T VOBIT 2 contains Voglibose (0.2mg), an alpha-glucosidase inhibitor used in the management of type 2 diabetes mellitus. It works by reversibly inhibiting alpha-glucosidase enzymes in the small intestine, which are responsible for breaking down complex carbohydrates into absorbable monosaccharides. This action delays the digestion and absorption of carbohydrates, thereby reducing the postprandial (after-meal) rise in blood glucose levels. Voglibose is particularly effective in controlling post-meal hyperglycemia, a common challenge in diabetes management.

It is often used as an adjunct to diet and exercise, and can be combined with other oral antidiabetic agents or insulin. Voglibose helps to flatten the glucose curve after meals, contributing to overall better glycemic control without directly stimulating insulin secretion, thus carrying a low risk of hypoglycemia when used as monotherapy.

Uses

• Management of postprandial hyperglycemia
• Treatment of type 2 diabetes mellitus
• Management of impaired glucose tolerance
• Adjunct to diet and exercise

Directions For Use

Take orally, usually three times daily, immediately before meals, or as advised by your physician.

Benefits

• Reduces post-meal blood sugar spikes
• Helps manage type 2 diabetes
• Low risk of hypoglycemia when used alone
• Improves overall glycemic control
• Can be combined with other antidiabetics
• Weight neutral

Side Effects

• Flatulence
• Abdominal distension
• Diarrhea
• Abdominal pain
• Nausea
• Vomiting
• Indigestion
• Elevated liver enzymes (rare)
• Skin rash (rare)
• Headache
• Dizziness
• Constipation

Safety Measures

• Alcohol - Use with caution, as alcohol can affect blood sugar levels and may exacerbate gastrointestinal side effects.
• Pregnancy - Not recommended during pregnancy. Consult your doctor for appropriate management.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if it passes into breast milk. Consult your doctor.
• Liver - Contraindicated in patients with severe hepatic impairment. Regular monitoring of liver function is advised.
• Kidney - Contraindicated in patients with severe renal impairment. Regular monitoring of kidney function is advised.
• Lung - No direct lung effects. However, severe gastrointestinal discomfort (e.g., abdominal distension) might indirectly affect breathing in some individuals.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.